<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416661</url>
  </required_header>
  <id_info>
    <org_study_id>LP 06-2018</org_study_id>
    <nct_id>NCT02416661</nct_id>
  </id_info>
  <brief_title>Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease</brief_title>
  <acronym>LYSO-PROOF</acronym>
  <official_title>Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, epidemiological study to demonstrate the correlation and&#xD;
      predictive value of lyso-Gb1 concentration with the clinical severity of na誰ve, initially&#xD;
      non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1&#xD;
      patients and to correlate lyso-Gb1 concentration with the clinical improvement of ERT or SRT&#xD;
      treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gaucher disease is an autosomal recessive inherited lysosomal storage disorder. The disease&#xD;
      is caused by the hereditary deficiency of the glucocerebrosidase, a lysosomal enzyme that&#xD;
      breaks down glucocerebroside into glucose and ceramide.&#xD;
&#xD;
      To date a definitive diagnosis of Gaucher's disease can only be made applying biochemical&#xD;
      testing measuring the reduced enzymatic activity of the beta-glucosidase together with&#xD;
      genetic confirmation. Since numerous different mutations may be the cause of a particular&#xD;
      lysosomal storage disease the sequencing of the entire beta-glucosidase gene is applied in&#xD;
      Gaucher's disease in order to confirm the genetic diagnosis.&#xD;
&#xD;
      The use of primary storage molecules as biomarker was assessed for glucosylceramide (Gb1) in&#xD;
      plasma of Gaucher's disease patients and compared to the level of Gb1 in healthy individuals.&#xD;
&#xD;
      In order to establish a sensitive and specific biomarker for GD, we compared mass spectra of&#xD;
      the plasma of healthy controls and GD patients using HPLC and tandem mass spectrometry. Mass&#xD;
      spectra that differed most between patients and controls were analysed in more detail. The&#xD;
      resulting biomarker, which was patented in June 2011 (PCT/EP2012/002409), was lyso - Gb1. We&#xD;
      identified this compound as a reliable, sensitive and specific biomarker for GD in a cohort&#xD;
      of GD patients. Furthermore, in a pilot study we evaluated whether lyso-Gb1 is related to the&#xD;
      specific genotypes and is reliable for long-term monitoring of the efficiency of therapy.&#xD;
&#xD;
      The aim this study is therefore to investigate lyso-Gb1 as a long-term prognostic marker in&#xD;
      na誰ve, non-ERT/SRT GD type 1 patients by monitoring over the course of 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">January 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrating the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of na誰ve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients</measure>
    <time_frame>48 month</time_frame>
    <description>lyso-Gb1 will be analzyed via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlating lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3.</measure>
    <time_frame>48 month</time_frame>
    <description>lyso-Gb1 will be analysed over a period of 36 months via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) to demonstrate the course of the biomarker.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">299</enrollment>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Gaucher Disease</condition>
  <condition>Sphingolipidoses</condition>
  <arm_group>
    <arm_group_label>Participants diagnosed with Gaucher disease</arm_group_label>
    <description>Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard速)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients aged 6 months or older with genetically confirmed diagnosis of&#xD;
        Gaucher disease type 1 without treatment prior to enrollment or no treatment for more than&#xD;
        24 months ago&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 6 months or older&#xD;
&#xD;
          -  Patients with genetically confirmed diagnosis of Gaucher disease type 1&#xD;
&#xD;
          -  No prior treatment with enzyme replacement therapy or substrate reduction therapy ro&#xD;
             no traetment for more than 24 months&#xD;
&#xD;
          -  Signed informed consent by parents/legal guardian and patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male or female patients being younger than 6 months&#xD;
&#xD;
          -  Patients without genetically confirmed diagnosis of Gaucher disease type 1&#xD;
&#xD;
          -  Gaucher disease 2 or 3&#xD;
&#xD;
          -  Patient is currently undergoing enzyme replacement therapy or substrate reduction&#xD;
             therapy&#xD;
&#xD;
          -  Missing signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>CENTOGENE GmbH Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>10001</zip>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki, Ippokration General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Human Genetics</name>
      <address>
        <city>Bangalore</city>
        <zip>560100</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103 102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children hospital</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital d'Enfant</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital and the Institute of Child Health</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge (planta 7.1)</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Greece</country>
    <country>India</country>
    <country>Israel</country>
    <country>Morocco</country>
    <country>Pakistan</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Iran, Islamic Republic of</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Tunisia</country>
    <country>United States</country>
    <country>Venezuela</country>
  </removed_countries>
  <link>
    <url>http://www.centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gaucher Disease type 1</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lipid Metabolism, Inborn Errors</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Lipidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Sphingolipidoses</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

